TSHA
Taysha Gene Therapies Inc.
$2.87
+$0.04(+1.41%)
80
Overall
--
Value
80
Tech
--
Quality
Market Cap
$774.74M
Volume
2.26M
52W Range
$1.05 - $3.40
Target Price
$8.67
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | -- | $2.5M | $15.5M | $8.3M | ||
| Total Revenue | -- | -- | $2.5M | $15.5M | $8.3M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | -- | $2.5M | $15.5M | $8.3M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $43.0M | $173.3M | $128.5M | $87.9M | $99.8M | ||
| Research & Development | $31.9M | $131.9M | $91.2M | $56.8M | $66.0M | ||
| Research Expense | $31.9M | $131.9M | $91.2M | $56.8M | $66.0M | ||
| Selling, General & Administrative | $11.1M | $41.3M | $37.4M | $30.0M | $29.0M | ||
| General & Administrative Expenses | $11.1M | $41.3M | $37.4M | $30.0M | $29.0M | ||
| Salaries & Wages | -- | -- | -- | $26.5M | $36.4M | ||
| Depreciation & Amortization | $9.0K | $492.0K | $1.2M | $1.4M | $1.2M | ||
| Depreciation & Amortization | $9.0K | $492.0K | $1.2M | $1.4M | $1.2M | ||
| Other Operating Expenses | -- | -- | $3.3M | $3.7M | $3.5M | ||
| OPERATING INCOME | |||||||
| Operating income | $-43.0M | $-173.3M | $-162.4M | $-72.4M | $-91.5M | ||
| EBITDA | $-60.0M | $-172.6M | $-161.0M | $-104.1M | $-86.8M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $28.0K | $1.4M | $3.8M | $4.9M | -- | ||
| Intinc | $49.0K | $172.0K | $249.0K | $3.6M | $6.9M | ||
| Net Non-Operating Interest Income/Expense | $21.0K | $-1.3M | $-3.5M | $3.6M | $6.9M | ||
| Other Income/Expense | $17.0M | $-52.2M | $-36.4M | $2.5M | $4.9M | ||
| Other Special Charges | $-17.0M | $52.2M | $-18.0K | $-1.4M | $-110.0K | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | -- | -- | $-500.0K | $-4.8M | ||
| Impairment of Capital Assets | -- | -- | -- | $500.0K | $4.8M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-60.0M | $-173.1M | $-162.2M | $-106.7M | $-89.3M | ||
| Pre-Tax Income | $-60.0M | $-174.5M | $-166.0M | $-70.3M | $-89.3M | ||
| NET INCOME | |||||||
| Net Income | $-60.0M | $-174.5M | $-166.0M | $-111.6M | $-89.3M | ||
| Net Income (Continuing Operations) | $-60.0M | $-174.5M | $-166.0M | $-111.6M | $-89.3M | ||
| Net Income (Discontinued Operations) | $-60.0M | $-174.5M | $-166.0M | $-111.6M | $-89.3M | ||
| Net Income (Common Stockholders) | $-60.0M | $-174.5M | $-166.0M | $-111.6M | $-89.3M | ||
| Normalized Income | -- | -- | -- | -- | $-69.3M | ||
| TOTALS | |||||||
| Total Expenses | $43.0M | $173.3M | $128.5M | $87.9M | $99.8M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $17.7M | $37.7M | $44.0M | $116.1M | $250.1M | ||
| Average Shares Outstanding (Diluted) | $17.7M | -- | $44.0M | $116.1M | $250.1M | ||
| Shares Outstanding | $37.8M | $38.5M | $63.5M | $187.0M | $205.0M | ||
| Basic EPS | $-3.4 | $-4.64 | $-3.78 | $-0.96 | $-0.36 | ||
| Basic EPS (Continuing Operations) | $-3.4 | $-4.64 | $-3.78 | $-0.96 | $-0.36 | ||
| Diluted EPS | $-3.4 | $-4.64 | $-3.78 | $-0.96 | $-0.36 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.78 | $-0.96 | $-0.36 | ||
| OTHER METRICS | |||||||
| Gain On Sale Of P P E | -- | -- | -- | $-600.0K | $-4.8M | ||
| Other Gand A | $11.1M | $41.3M | $37.4M | $30.0M | $29.0M | ||
| Other Impairment Of Capital Assets | -- | -- | $36.4M | $1.1M | $4.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TSHA | $2.87 | +1.4% | 2.26M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Taysha Gene Therapies Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW